Gilead Sciences (GILD) vs Johnson & Johnson (JNJ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Johnson & Johnson (JNJ) has outperformed Gilead Sciences (GILD) over the past year, gaining 36.8% versus a gain of 25.7%. Over five years, GILD leads with a +117.1% price change compared with +60.2% for JNJ. Johnson & Johnson is the larger company by market cap ($618.09 billion vs $182.40 billion), about 3.4 times the size.
On valuation, Gilead Sciences trades at a lower forward P/E (14.9x vs 21.2x for Johnson & Johnson). Gilead Sciences offers the higher dividend yield (2.19% vs 2.04%). Gilead Sciences converts more of its revenue into profit, with a net margin of 28.9% versus 28.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GILD | JNJ |
|---|---|---|
| Share price | $147.10 | $256.48 |
| Market cap | $182.40B | $618.09B |
| 1-day change | +0.17% | -0.76% |
| YTD return | +19.64% | +24.89% |
| 1-year return | +25.75% | +36.83% |
| 5-year return | +117.14% | +60.23% |
| P/E ratio (TTM) | — | 29.72 |
| Forward P/E | 14.87 | 21.19 |
| EPS (TTM) | $-2.65 | $8.63 |
| Dividend yield | 2.19% | 2.04% |
| Annual dividend | $3.22 | $5.24 |
| Revenue (latest FY) | $29.44B | $94.19B |
| Revenue growth (YoY) | +2.40% | +6.05% |
| Net income (latest FY) | $8.51B | $26.80B |
| Gross margin | 78.83% | 67.88% |
| Operating margin | 34.04% | — |
| Net margin | 28.90% | 28.46% |
| 52-week high | $157.29 | $281.07 |
| 52-week low | $114.02 | $184.66 |
| Distance from 52-week high | -6.48% | -8.75% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +8.27% | +9.03% |
| Average volume | 6.01M | 7.02M |
| Shares outstanding | 1.24B | 2.41B |
| Employees | 17,000 | 138,200 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Johnson & Johnson is about 3.4 times larger than Gilead Sciences by market value ($618.09B vs $182.40B).
- JNJ has outperformed GILD by 11.1 percentage points over the past year.
About Gilead Sciences
GILD stock →Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17,000 employees
About Johnson & Johnson
JNJ stock →Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech.
Health Care · Biotechnology: Pharmaceutical Preparations · 138,200 employees
GILD vs JNJ FAQ
Which is bigger, Gilead Sciences or Johnson & Johnson?
Johnson & Johnson (JNJ) is larger, with a market capitalization of $618.09B compared with $182.40B for Gilead Sciences (GILD).
Which stock has performed better over the past year, GILD or JNJ?
JNJ returned +36.83% over the past 12 months, compared with +25.75% for GILD (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Gilead Sciences or Johnson & Johnson?
Gilead Sciences has the higher yield at 2.19%, compared with 2.04% for Johnson & Johnson.
Are Gilead Sciences and Johnson & Johnson in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Gilead Sciences and Biotechnology: Pharmaceutical Preparations for Johnson & Johnson.